How I manage mantle cell lymphoma: indolent versus aggressive disease.
Wilson MR, Barrett A, Cheah CY, Eyre TA.
Br J Haematol. 2023 Apr;201(2):185-198. doi: 10.1111/bjh.18697. Epub 2023 Feb 20.
Non-Hodgkin lymphoma.
Armitage JO, Gascoyne RD, Lunning MA, Cavalli F.
Lancet. 2017 Jul 15;390(10091):298-310. doi: 10.1016/S0140-6736(16)32407-2. Epub 2017 Jan 31.
Lymphoma.
Mugnaini EN, Ghosh N.
Prim Care. 2016 Dec;43(4):661-675. doi: 10.1016/j.pop.2016.07.012.
Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA.
Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71. doi: 10.1016/j.critrevonc.2012.12.009. Epub 2013 Jan 30.
Childhood aggressive B-cell non-Hodgkin lymphoma in low-middle-income countries.
Moleti ML, Testi AM, Foà R.
Br J Haematol. 2022 Feb;196(4):849-863. doi: 10.1111/bjh.17979. Epub 2021 Dec 6.
Aggressive non-Hodgkin lymphoma in the pediatric and young adult population; diagnostic and molecular pearls of wisdom.
Singh A, Obiorah IE.
Semin Diagn Pathol. 2023 Nov;40(6):392-400. doi: 10.1053/j.semdp.2023.06.002. Epub 2023 Jun 22.
PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
Phillips EH, Iype R, Wirth A.
Br J Radiol. 2021 Nov 1;94(1127):20210576. doi: 10.1259/bjr.20210576. Epub 2021 Sep 14.
Strategies for aggressive T-cell lymphoma: divide and conquer.
Pinter-Brown LC.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):154-159. doi: 10.1182/hematology.2020000101.
Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review.
Khanmohammadi S, Fallahtafti P.
J Cell Mol Med. 2023 Jul;27(14):1928-1946. doi: 10.1111/jcmm.17795. Epub 2023 May 29.
Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma.
Moffitt AB, Dave SS.
J Clin Oncol. 2017 Mar 20;35(9):955-962. doi: 10.1200/JCO.2016.71.7603. Epub 2017 Feb 13.
